Intercell AG

euro adhoc: Intercell AG
Joint Ventures/Cooperation/Collaboration
Intercell receives EUR 1 million milestone payment from partner sanofi pasteur for bacterial vaccine candidate

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Vienna (Austria), January 9, 2006 - Intercell AG (VSE, "ICLL") announced today that the next milestone within the collaboration with sanofi pasteur for the development of a bacterial vaccine has successfully been achieved. This significant progress within the preclinical development of a bacterial vaccine candidate resulted in another milestone payment of EUR 1 million for Intercell.

In July 2005, sanofi pasteur exercised its option on exclusive worldwide commercial rights on certain bacterial vaccine antigens, which have been identified by Intercell’s Antigen Identification Program. Over the entire term of the agreement, Intercell will be entitled to further milestone based license payments totaling to about EUR 20 million, as well as royalties on future net sales. The EUR 1 million milestone payment received now will be accounted for as revenue of the financial year 2005.

The vaccine candidate, which has the potential to address an important unmet medical need in the field of infectious diseases, was licensed from Intercell under a collaboration and license option agreement signed in December 2003. The parties have agreed confidentiality on the indication.

"We’re pleased about this significant progress in the development of a bacterial vaccine candidate fully derived from our proprietary Antigen Identification Program within our collaboration with sanofi pasteur," commented Gerd Zettlmeissl, CEO of Intercell AG. "This emphasizes once again the value and potential of our technologies for the development of novel vaccines."

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

@@start.t2@@end of announcement                                                 euro adhoc 09.01.2006 07:10:55

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: